Masimo Corporation (MASI) Stock Competitors & Peer Comparison

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MASI is priced at $179.95, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MASI's ROE is +0.09%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BSX-PA's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ABT has a market cap of 158.9B. Regarding current trading prices, MASI is priced at $179.95, while ABT trades at $91.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ABT's P/E ratio is 25.70. In terms of profitability, MASI's ROE is +0.09%, compared to ABT's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ABT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ISRG has a market cap of 151.1B. Regarding current trading prices, MASI is priced at $179.95, while ISRG trades at $426.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ISRG's P/E ratio is 51.71. In terms of profitability, MASI's ROE is +0.09%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, MASI is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ISRG's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SYK has a market cap of 120.4B. Regarding current trading prices, MASI is priced at $179.95, while SYK trades at $314.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SYK's P/E ratio is 36.31. In terms of profitability, MASI's ROE is +0.09%, compared to SYK's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SYK's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, MASI is priced at $179.95, while MDT trades at $81.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas MDT's P/E ratio is 21.98. In terms of profitability, MASI's ROE is +0.09%, compared to MDT's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check MDT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BSX has a market cap of 72.7B. Regarding current trading prices, MASI is priced at $179.95, while BSX trades at $48.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BSX's P/E ratio is 20.47. In terms of profitability, MASI's ROE is +0.09%, compared to BSX's ROE of +0.15%. Regarding short-term risk, MASI is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BSX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BRKRP has a market cap of 64.6B. Regarding current trading prices, MASI is priced at $179.95, while BRKRP trades at $425.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BRKRP's P/E ratio is N/A. In terms of profitability, MASI's ROE is +0.09%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, MASI is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BRKRP's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, EW has a market cap of 50.4B. Regarding current trading prices, MASI is priced at $179.95, while EW trades at $87.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas EW's P/E ratio is 47.31. In terms of profitability, MASI's ROE is +0.09%, compared to EW's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check EW's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, DXCM has a market cap of 30.2B. Regarding current trading prices, MASI is priced at $179.95, while DXCM trades at $78.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas DXCM's P/E ratio is 33.56. In terms of profitability, MASI's ROE is +0.09%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, MASI is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check DXCM's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, RMD has a market cap of 28.6B. Regarding current trading prices, MASI is priced at $179.95, while RMD trades at $196.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas RMD's P/E ratio is 19.00. In terms of profitability, MASI's ROE is +0.09%, compared to RMD's ROE of +0.24%. Regarding short-term risk, MASI is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check RMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, MASI is priced at $179.95, while PHG trades at $26.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PHG's P/E ratio is 22.84. In terms of profitability, MASI's ROE is +0.09%, compared to PHG's ROE of +0.09%. Regarding short-term risk, MASI is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PHG's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, STE has a market cap of 20.8B. Regarding current trading prices, MASI is priced at $179.95, while STE trades at $212.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas STE's P/E ratio is 26.88. In terms of profitability, MASI's ROE is +0.09%, compared to STE's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check STE's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ZBH has a market cap of 17.3B. Regarding current trading prices, MASI is priced at $179.95, while ZBH trades at $89.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ZBH's P/E ratio is 23.22. In terms of profitability, MASI's ROE is +0.09%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, MASI is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ZBH's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MASI is priced at $179.95, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MASI's ROE is +0.09%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ABMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, MASI is priced at $179.95, while SNN trades at $31.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SNN's P/E ratio is 21.91. In terms of profitability, MASI's ROE is +0.09%, compared to SNN's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SNN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ALGN has a market cap of 12.8B. Regarding current trading prices, MASI is priced at $179.95, while ALGN trades at $178.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ALGN's P/E ratio is 29.93. In terms of profitability, MASI's ROE is +0.09%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ALGN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, MASI is priced at $179.95, while PEN trades at $321.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PEN's P/E ratio is 74.16. In terms of profitability, MASI's ROE is +0.09%, compared to PEN's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PEN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MASI is priced at $179.95, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MASI's ROE is +0.09%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MASI is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SWAV's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, MASI is priced at $179.95, while GMED trades at $82.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas GMED's P/E ratio is 19.29. In terms of profitability, MASI's ROE is +0.09%, compared to GMED's ROE of +0.13%. Regarding short-term risk, MASI is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check GMED's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PODD has a market cap of 11.1B. Regarding current trading prices, MASI is priced at $179.95, while PODD trades at $159.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PODD's P/E ratio is 37.29. In terms of profitability, MASI's ROE is +0.09%, compared to PODD's ROE of +0.21%. Regarding short-term risk, MASI is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PODD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, MASI is priced at $179.95, while BRKR trades at $57.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BRKR's P/E ratio is -238.50. In terms of profitability, MASI's ROE is +0.09%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, MASI is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BRKR's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, MASI is priced at $179.95, while BIO-B trades at $307.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BIO-B's P/E ratio is 51.10. In terms of profitability, MASI's ROE is +0.09%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, MASI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check BIO-B's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BIO has a market cap of 8B. Regarding current trading prices, MASI is priced at $179.95, while BIO trades at $297.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BIO's P/E ratio is 49.57. In terms of profitability, MASI's ROE is +0.09%, compared to BIO's ROE of +0.02%. Regarding short-term risk, MASI is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BIO's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, GKOS has a market cap of 7.4B. Regarding current trading prices, MASI is priced at $179.95, while GKOS trades at $126.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas GKOS's P/E ratio is -38.21. In terms of profitability, MASI's ROE is +0.09%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, MASI is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check GKOS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MASI is priced at $179.95, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas NARI's P/E ratio is -59.24. In terms of profitability, MASI's ROE is +0.09%, compared to NARI's ROE of -0.00%. Regarding short-term risk, MASI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check NARI's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, MASI is priced at $179.95, while LIVN trades at $77.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas LIVN's P/E ratio is 39.37. In terms of profitability, MASI's ROE is +0.09%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, MASI is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check LIVN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, MASI is priced at $179.95, while IRTC trades at $113.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas IRTC's P/E ratio is -133.92. In terms of profitability, MASI's ROE is +0.09%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, MASI is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check IRTC's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, MASI is priced at $179.95, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AXNX's P/E ratio is -709.80. In terms of profitability, MASI's ROE is +0.09%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, MASI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check AXNX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, MASI is priced at $179.95, while ITGR trades at $94.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ITGR's P/E ratio is 23.36. In terms of profitability, MASI's ROE is +0.09%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, MASI is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ITGR's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, MASI is priced at $179.95, while TMDX trades at $74.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas TMDX's P/E ratio is 17.00. In terms of profitability, MASI's ROE is +0.09%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, MASI is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check TMDX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, MASI is priced at $179.95, while ESTA trades at $79.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ESTA's P/E ratio is -54.30. In terms of profitability, MASI's ROE is +0.09%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, MASI is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ESTA's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, MASI is priced at $179.95, while AXGN trades at $42.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AXGN's P/E ratio is -66.98. In terms of profitability, MASI's ROE is +0.09%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, MASI is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check AXGN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MASI is priced at $179.95, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MASI's ROE is +0.09%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MASI is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check NUVA's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, MASI is priced at $179.95, while UFPT trades at $231.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas UFPT's P/E ratio is 26.32. In terms of profitability, MASI's ROE is +0.09%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, MASI is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check UFPT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, MASI is priced at $179.95, while PRCT trades at $28.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PRCT's P/E ratio is -15.73. In terms of profitability, MASI's ROE is +0.09%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, MASI is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PRCT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, MASI is priced at $179.95, while IART trades at $17.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas IART's P/E ratio is -2.77. In terms of profitability, MASI's ROE is +0.09%, compared to IART's ROE of -0.48%. Regarding short-term risk, MASI is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check IART's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, MASI is priced at $179.95, while ENOV trades at $23.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ENOV's P/E ratio is -1.20. In terms of profitability, MASI's ROE is +0.09%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, MASI is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ENOV's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BFLY has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95, while BFLY trades at $5.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BFLY's P/E ratio is -17.07. In terms of profitability, MASI's ROE is +0.09%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, MASI is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BFLY's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95, while AHCO trades at $9.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AHCO's P/E ratio is -16.63. In terms of profitability, MASI's ROE is +0.09%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, MASI is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check AHCO's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MASI's ROE is +0.09%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MASI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check HSKA's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, MASI is priced at $179.95, while ATEC trades at $8.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ATEC's P/E ratio is -9.95. In terms of profitability, MASI's ROE is +0.09%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, MASI is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ATEC's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, MASI is priced at $179.95, while IRMD trades at $96.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas IRMD's P/E ratio is 52.69. In terms of profitability, MASI's ROE is +0.09%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, MASI is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check IRMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, MASI is priced at $179.95, while INSP trades at $42.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas INSP's P/E ratio is 9.59. In terms of profitability, MASI's ROE is +0.09%, compared to INSP's ROE of +0.18%. Regarding short-term risk, MASI is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check INSP's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, MASI is priced at $179.95, while TNDM trades at $17.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas TNDM's P/E ratio is -12.85. In terms of profitability, MASI's ROE is +0.09%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, MASI is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check TNDM's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, MASI is priced at $179.95, while AVNS trades at $25.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AVNS's P/E ratio is -15.64. In terms of profitability, MASI's ROE is +0.09%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, MASI is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check AVNS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SILK's P/E ratio is -18.96. In terms of profitability, MASI's ROE is +0.09%, compared to SILK's ROE of -0.35%. Regarding short-term risk, MASI is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SILK's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95, while CNMD trades at $36.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CNMD's P/E ratio is 20.85. In terms of profitability, MASI's ROE is +0.09%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, MASI is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CNMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MASI is priced at $179.95, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas FNA's P/E ratio is -19.83. In terms of profitability, MASI's ROE is +0.09%, compared to FNA's ROE of -0.35%. Regarding short-term risk, MASI is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check FNA's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, MASI is priced at $179.95, while AORT trades at $20.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AORT's P/E ratio is 83.48. In terms of profitability, MASI's ROE is +0.09%, compared to AORT's ROE of +0.03%. Regarding short-term risk, MASI is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check AORT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MASI is priced at $179.95, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CSII's P/E ratio is -20.83. In terms of profitability, MASI's ROE is +0.09%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MASI is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CSII's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, LMRI has a market cap of 831.1M. Regarding current trading prices, MASI is priced at $179.95, while LMRI trades at $8.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas LMRI's P/E ratio is -22.18. In terms of profitability, MASI's ROE is +0.09%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, MASI is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check LMRI's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, INMD has a market cap of 824.6M. Regarding current trading prices, MASI is priced at $179.95, while INMD trades at $13.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas INMD's P/E ratio is 10.04. In terms of profitability, MASI's ROE is +0.09%, compared to INMD's ROE of +0.13%. Regarding short-term risk, MASI is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check INMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SSII has a market cap of 726.5M. Regarding current trading prices, MASI is priced at $179.95, while SSII trades at $3.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SSII's P/E ratio is -72.60. In terms of profitability, MASI's ROE is +0.09%, compared to SSII's ROE of -0.23%. Regarding short-term risk, MASI is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SSII's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, MASI is priced at $179.95, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CRY's P/E ratio is 425.71. In terms of profitability, MASI's ROE is +0.09%, compared to CRY's ROE of +0.03%. Regarding short-term risk, MASI is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CRY's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CBLL has a market cap of 701.9M. Regarding current trading prices, MASI is priced at $179.95, while CBLL trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CBLL's P/E ratio is -11.42. In terms of profitability, MASI's ROE is +0.09%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, MASI is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CBLL's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SIBN has a market cap of 688.7M. Regarding current trading prices, MASI is priced at $179.95, while SIBN trades at $15.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SIBN's P/E ratio is -39.82. In terms of profitability, MASI's ROE is +0.09%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, MASI is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SIBN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BVS has a market cap of 623.3M. Regarding current trading prices, MASI is priced at $179.95, while BVS trades at $9.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BVS's P/E ratio is 22.44. In terms of profitability, MASI's ROE is +0.09%, compared to BVS's ROE of +0.16%. Regarding short-term risk, MASI is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BVS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, MASI is priced at $179.95, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SRDX's P/E ratio is -34.66. In terms of profitability, MASI's ROE is +0.09%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, MASI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check SRDX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, TCMD has a market cap of 594.1M. Regarding current trading prices, MASI is priced at $179.95, while TCMD trades at $26.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas TCMD's P/E ratio is 30.28. In terms of profitability, MASI's ROE is +0.09%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, MASI is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check TCMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MASI is priced at $179.95, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas APEN's P/E ratio is -9.43. In terms of profitability, MASI's ROE is +0.09%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MASI is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check APEN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BWAY has a market cap of 566M. Regarding current trading prices, MASI is priced at $179.95, while BWAY trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BWAY's P/E ratio is 65.59. In terms of profitability, MASI's ROE is +0.09%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, MASI is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BWAY's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, NPCE has a market cap of 544.1M. Regarding current trading prices, MASI is priced at $179.95, while NPCE trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas NPCE's P/E ratio is -24.55. In terms of profitability, MASI's ROE is +0.09%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, MASI is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check NPCE's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, MASI is priced at $179.95, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, MASI's ROE is +0.09%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, MASI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check ZIMV's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CTKB has a market cap of 533.4M. Regarding current trading prices, MASI is priced at $179.95, while CTKB trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CTKB's P/E ratio is -7.12. In terms of profitability, MASI's ROE is +0.09%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, MASI is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CTKB's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CERS has a market cap of 517M. Regarding current trading prices, MASI is priced at $179.95, while CERS trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CERS's P/E ratio is -51.60. In terms of profitability, MASI's ROE is +0.09%, compared to CERS's ROE of -0.15%. Regarding short-term risk, MASI is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CERS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PMI has a market cap of 492.5M. Regarding current trading prices, MASI is priced at $179.95, while PMI trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PMI's P/E ratio is -0.42. In terms of profitability, MASI's ROE is +0.09%, compared to PMI's ROE of +4.99%. Regarding short-term risk, MASI is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PMI's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, KIDS has a market cap of 474.9M. Regarding current trading prices, MASI is priced at $179.95, while KIDS trades at $18.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas KIDS's P/E ratio is -11.01. In terms of profitability, MASI's ROE is +0.09%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, MASI is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check KIDS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, VREX has a market cap of 447.1M. Regarding current trading prices, MASI is priced at $179.95, while VREX trades at $10.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas VREX's P/E ratio is -5.31. In terms of profitability, MASI's ROE is +0.09%, compared to VREX's ROE of -0.18%. Regarding short-term risk, MASI is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check VREX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PACB has a market cap of 425.5M. Regarding current trading prices, MASI is priced at $179.95, while PACB trades at $1.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PACB's P/E ratio is -3.34. In terms of profitability, MASI's ROE is +0.09%, compared to PACB's ROE of -4.88%. Regarding short-term risk, MASI is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PACB's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CLPT has a market cap of 407.6M. Regarding current trading prices, MASI is priced at $179.95, while CLPT trades at $13.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CLPT's P/E ratio is -13.59. In terms of profitability, MASI's ROE is +0.09%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, MASI is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CLPT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, DCTH has a market cap of 403.6M. Regarding current trading prices, MASI is priced at $179.95, while DCTH trades at $11.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas DCTH's P/E ratio is 1169.00. In terms of profitability, MASI's ROE is +0.09%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, MASI is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check DCTH's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, OFIX has a market cap of 399M. Regarding current trading prices, MASI is priced at $179.95, while OFIX trades at $9.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas OFIX's P/E ratio is -6.58. In terms of profitability, MASI's ROE is +0.09%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, MASI is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check OFIX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, VMD has a market cap of 380.3M. Regarding current trading prices, MASI is priced at $179.95, while VMD trades at $9.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas VMD's P/E ratio is 26.81. In terms of profitability, MASI's ROE is +0.09%, compared to VMD's ROE of +0.11%. Regarding short-term risk, MASI is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check VMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, AVR has a market cap of 348.4M. Regarding current trading prices, MASI is priced at $179.95, while AVR trades at $9.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas AVR's P/E ratio is -4.27. In terms of profitability, MASI's ROE is +0.09%, compared to AVR's ROE of -1.24%. Regarding short-term risk, MASI is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check AVR's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, LAB has a market cap of 345.9M. Regarding current trading prices, MASI is priced at $179.95, while LAB trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas LAB's P/E ratio is -6.82. In terms of profitability, MASI's ROE is +0.09%, compared to LAB's ROE of -0.21%. Regarding short-term risk, MASI is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check LAB's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, MASI is priced at $179.95, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SMLR's P/E ratio is 3.92. In terms of profitability, MASI's ROE is +0.09%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, MASI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check SMLR's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SENS has a market cap of 310.4M. Regarding current trading prices, MASI is priced at $179.95, while SENS trades at $7.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SENS's P/E ratio is -3.77. In terms of profitability, MASI's ROE is +0.09%, compared to SENS's ROE of -1.30%. Regarding short-term risk, MASI is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SENS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, MASS has a market cap of 302.1M. Regarding current trading prices, MASI is priced at $179.95, while MASS trades at $7.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas MASS's P/E ratio is -8.24. In terms of profitability, MASI's ROE is +0.09%, compared to MASS's ROE of -0.26%. Regarding short-term risk, MASI is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check MASS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ELMD has a market cap of 301.8M. Regarding current trading prices, MASI is priced at $179.95, while ELMD trades at $36.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ELMD's P/E ratio is 31.15. In terms of profitability, MASI's ROE is +0.09%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, MASI is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ELMD's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, SGHT has a market cap of 263.9M. Regarding current trading prices, MASI is priced at $179.95, while SGHT trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas SGHT's P/E ratio is -6.93. In terms of profitability, MASI's ROE is +0.09%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, MASI is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check SGHT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, MASI is priced at $179.95, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas MGRM's P/E ratio is -11.11. In terms of profitability, MASI's ROE is +0.09%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, MASI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check MGRM's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, TMCI has a market cap of 242M. Regarding current trading prices, MASI is priced at $179.95, while TMCI trades at $3.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas TMCI's P/E ratio is -3.89. In terms of profitability, MASI's ROE is +0.09%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, MASI is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check TMCI's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CATX has a market cap of 231.4M. Regarding current trading prices, MASI is priced at $179.95, while CATX trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CATX's P/E ratio is -2.12. In terms of profitability, MASI's ROE is +0.09%, compared to CATX's ROE of -0.42%. Regarding short-term risk, MASI is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CATX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MASI is priced at $179.95, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MASI's ROE is +0.09%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MASI is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check NVRO's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, MASI is priced at $179.95, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas EYES's P/E ratio is N/A. In terms of profitability, MASI's ROE is +0.09%, compared to EYES's ROE of -2.64%. Regarding short-term risk, MASI is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check EYES's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, PROF has a market cap of 206.4M. Regarding current trading prices, MASI is priced at $179.95, while PROF trades at $6.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas PROF's P/E ratio is -5.50. In terms of profitability, MASI's ROE is +0.09%, compared to PROF's ROE of -0.71%. Regarding short-term risk, MASI is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check PROF's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, APYX has a market cap of 203.5M. Regarding current trading prices, MASI is priced at $179.95, while APYX trades at $4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas APYX's P/E ratio is -22.09. In terms of profitability, MASI's ROE is +0.09%, compared to APYX's ROE of -0.91%. Regarding short-term risk, MASI is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check APYX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, RXST has a market cap of 203.3M. Regarding current trading prices, MASI is priced at $179.95, while RXST trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas RXST's P/E ratio is -4.35. In terms of profitability, MASI's ROE is +0.09%, compared to RXST's ROE of -0.17%. Regarding short-term risk, MASI is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check RXST's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, ANIK has a market cap of 193.9M. Regarding current trading prices, MASI is priced at $179.95, while ANIK trades at $14.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas ANIK's P/E ratio is -18.21. In terms of profitability, MASI's ROE is +0.09%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, MASI is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check ANIK's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, MASI is priced at $179.95, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas BSGM's P/E ratio is -5.81. In terms of profitability, MASI's ROE is +0.09%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, MASI is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check BSGM's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, MASI is priced at $179.95, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas MDGS's P/E ratio is -0.27. In terms of profitability, MASI's ROE is +0.09%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, MASI is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check MDGS's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, MASI is priced at $179.95, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas EDAP's P/E ratio is -5.80. In terms of profitability, MASI's ROE is +0.09%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, MASI is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check EDAP's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, INGN has a market cap of 171.9M. Regarding current trading prices, MASI is priced at $179.95, while INGN trades at $6.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas INGN's P/E ratio is -6.98. In terms of profitability, MASI's ROE is +0.09%, compared to INGN's ROE of -0.13%. Regarding short-term risk, MASI is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check INGN's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, FOCL has a market cap of 171.7M. Regarding current trading prices, MASI is priced at $179.95, while FOCL trades at $4.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas FOCL's P/E ratio is -5.59. In terms of profitability, MASI's ROE is +0.09%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, MASI is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check FOCL's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, MASI is priced at $179.95, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas QIPT's P/E ratio is -15.87. In terms of profitability, MASI's ROE is +0.09%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, MASI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for MASI.Check QIPT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, QTRX has a market cap of 145.6M. Regarding current trading prices, MASI is priced at $179.95, while QTRX trades at $3.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas QTRX's P/E ratio is -1.31. In terms of profitability, MASI's ROE is +0.09%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, MASI is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check QTRX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, CVRX has a market cap of 138M. Regarding current trading prices, MASI is priced at $179.95, while CVRX trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas CVRX's P/E ratio is -2.59. In terms of profitability, MASI's ROE is +0.09%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, MASI is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check CVRX's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, MXCT has a market cap of 127.5M. Regarding current trading prices, MASI is priced at $179.95, while MXCT trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas MXCT's P/E ratio is -3.31. In terms of profitability, MASI's ROE is +0.09%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, MASI is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check MXCT's competition here

MASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASI stands at 9.4B. In comparison, TLSI has a market cap of 126.6M. Regarding current trading prices, MASI is priced at $179.95, while TLSI trades at $3.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASI currently has a P/E ratio of 44.54, whereas TLSI's P/E ratio is -2.35. In terms of profitability, MASI's ROE is +0.09%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, MASI is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for MASI.Check TLSI's competition here